A Comprehensive Review of Emerging Therapies for Type 2 Diabetes and Their Cardiovascular Effects

被引：0

作者：

Acosta, G. Arnaldo J. ^{[1
]}

Chitneni, Eesha ^{[2
]}

Vidals, Claudia Jeanette Manzanares ^{[3
]}

Modumudi, Sravani ^{[4
]}

Hammad, Sobia ^{[5
]}

Verma, Ashee ^{[6
]}

Rajesh, Rahul Y. ^{[7
]}

Khaliq, Aimen ^{[8
,9
]}

Adeyemi, Olaoluwa ^{[10
]}

Abid, Farhat ^{[11
]}

Gujar, Rucha, V ^{[12
]}

机构：

[1] Hosp Univ Dr Alfredo Grieken, Internal Med, Coro, Venezuela

[2] MediCiti Inst Med Sci, Internal Med, Hyderabad, Pakistan

[3] Gen Hosp Toluca Dr Nicolas San Juan, Internal Med, Toluca, Mexico

[4] Kamineni Acad Med Sci & Res Ctr, Internal Med, Hyderabad, Pakistan

[5] Jinnah Med & Dent Coll, Med, Karachi, Pakistan

[6] Ruxmaniben Deepchand Gardi Med Coll, Internal Med, Kota, India

[7] Tbilisi State Med Univ, Internal Med, Tbilisi, Georgia

[8] Liaquat Natl Hosp, Med, Karachi, Pakistan

[9] Med Coll, Karachi, Pakistan

[10] Richmond Gabriel Univ, Internal Med, Kingstown, St Vincent

[11] Quaid Eazam Med Coll, Gen Med, Bahawalpur, Pakistan

[12] Sir HN Reliance Fdn Hosp & Res Ctr, Internal Med, Mumbai, India

来源：

CUREUS JOURNAL OF MEDICAL SCIENCE | 2024年 / 16卷 / 07期

关键词：

ischemic heart diseases; advanced therapy; cardio vascular disease; diabetes mellitus; glp-1-r agonists; sglt2; inhibitors; DOUBLE-BLIND; INJURY; GLP-1; MULTICENTER; EFFICACY; SAFETY;

D O I：

10.7759/cureus.65707

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The discovery of inhibitors for sodium-glucose cotransporter 2 (SGLT2) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) has significantly improved type 2 diabetes management. Large-scale clinical studies have shown that both SGLT2 inhibitors and GLP-1 RA enhance cardiovascular health. Benefits include reduced cardiovascular disease risk, lower mortality, fewer heart failure hospitalizations (SGLT2 inhibitors), and stroke prevention (GLP-1 RA). Additionally, these drugs slow chronic kidney disease progression. This comprehensive treatment targets vascular events. Despite differences, both drug classes are crucial. GLP-1 RA mainly reduce stroke risk, while SGLT2 inhibitors alleviate heart failure. Our findings, based on a literature review, will address the renal and cardiac effects of SGLT2 inhibitors and GLP-1 RA in both diabetics and non-diabetics, highlighting their combined benefits for heart conditions.

引用

页数：12

共 57 条

[1] Glucagon-like peptide-1 receptor mediated control of cardiac energy [J].

Al Batran, Rami ;

Almutairi, Malak ;

Ussher, John R. .

PEPTIDES, 2018, 100 :94-100

[2] Interpreting global trends in type 2 diabetes complications and mortality [J].

Ali, Mohammed K. ;

Pearson-Stuttard, Jonathan ;

Selvin, Elizabeth ;

Gregg, Edward W. .

DIABETOLOGIA, 2022, 65 (01) :3-13

[3] The GLP-1 Receptor Agonist Liraglutide Increases Myocardial Glucose Oxidation Rates via Indirect Mechanisms and Mitigates Experimental Diabetic Cardiomyopathy [J].

Almutairi, Malak ;

Gopal, Keshav ;

Greenwell, Amanda A. ;

Young, Adrian ;

Gill, Robert ;

Aburasayn, Hanin ;

Al Batran, Rami ;

Chahade, Jadin J. ;

Gandhi, Manoj ;

Eaton, Farah ;

Mailloux, Ryan J. ;

Ussher, John R. .

CANADIAN JOURNAL OF CARDIOLOGY, 2021, 37 (01) :140-150

[4] 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021 [J].

不详 .

DIABETES CARE, 2021, 44 :S111-S124

[5] Trend analysis of cardiovascular disease mortality, incidence, and mortality-to-incidence ratio: results from global burden of disease study 2017 [J].

Amini, Maedeh ;

Zayeri, Farid ;

Salehi, Masoud .

BMC PUBLIC HEALTH, 2021, 21 (01)

[6] Empagliflozin in Heart Failure with a Preserved Ejection Fraction [J].

Anker, Stefan D. ;

Butler, Javed ;

Filippatos, Gerasimos ;

Ferreira, Joao P. ;

Bocchi, Edimar ;

Boehm, Michael ;

Brunner-La Rocca, Hans-Peter ;

Choi, Dong-Ju ;

Chopra, Vijay ;

Chuquiure-Valenzuela, Eduardo ;

Giannetti, Nadia ;

Gomez-Mesa, Juan Esteban ;

Janssens, Stefan ;

Januzzi, James L. ;

Gonzalez-Juanatey, Jose R. ;

Merkely, Bela ;

Nicholls, Stephen J. ;

Perrone, Sergio V. ;

Pina, Ileana L. ;

Ponikowski, Piotr ;

Senni, Michele ;

Sim, David ;

Spinar, Jindrich ;

Squire, Iain ;

Taddei, Stefano ;

Tsutsui, Hiroyuki ;

Verma, Subodh ;

Vinereanu, Dragos ;

Zhang, Jian ;

Carson, Peter ;

Lam, Carolyn Su Ping ;

Marx, Nikolaus ;

Zeller, Cordula ;

Sattar, Naveed ;

Jamal, Waheed ;

Schnaidt, Sven ;

Schnee, Janet M. ;

Brueckmann, Martina ;

Pocock, Stuart J. ;

Zannad, Faiez ;

Packer, Milton .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (16) :1451-1461

[7] Should metformin remain the first-line therapy for treatment of type 2 diabetes? [J].

Baker, Chelsea ;

Retzik-Stahr, Cimmaron ;

Singh, Vatsala ;

Plomondon, Renee ;

Anderson, Victoria ;

Rasouli, Neda .

THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2021, 12

[8] Ten things to know about ten cardiovascular disease risk factors [J].

Bays, Harold E. ;

Taub, Pam R. ;

Epstein, Elizabeth ;

Michos, Erin D. ;

Ferraro, Richard A. ;

Bailey, Alison L. ;

Kelli, Heval M. ;

Ferdinand, Keith C. ;

Echols, Melvin R. ;

Weintraub, Howard ;

Bostrom, John ;

Johnson, Heather M. ;

Hoppe, Kara K. ;

Shapiro, Michael D. ;

German, Charles A. ;

Virani, Salim S. ;

Hussain, Aliza ;

Ballantyne, Christie M. ;

Agha, Ali M. ;

Toth, Peter P. .

AMERICAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2021, 5

[9] Pharmaceutical Drugs and Natural Therapeutic Products for the Treatment of Type 2 Diabetes Mellitus [J].

Blahova, Jana ;

Martiniakova, Monika ;

Babikova, Martina ;

Kovacova, Veronika ;

Mondockova, Vladimira ;

Omelka, Radoslav .

PHARMACEUTICALS, 2021, 14 (08)

[10] Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease [J].

Bonnet, F. ;

Scheen, A. J. .

DIABETES & METABOLISM, 2018, 44 (06) :457-464

← 1 2 3 4 5 6 →